Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.

247wallst.com - 2026-07-15 12:27:23

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.

247wallst.com - 2026-07-15 09:10:09

These stocks offer a good mix of dividends, growth, and long-term stability.

fool.com - 2026-07-14 14:00:00

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

247wallst.com - 2026-07-14 11:51:03

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

zacks.com - 2026-07-14 11:31:03

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

fool.com - 2026-07-14 10:24:39

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

fool.com - 2026-07-14 05:00:00

In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.

zacks.com - 2026-07-13 18:45:15

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.

247wallst.com - 2026-07-13 16:47:09

The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

seekingalpha.com - 2026-07-13 13:45:49

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

marketbeat.com - 2026-07-13 12:25:30

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

seekingalpha.com - 2026-07-11 08:15:00

Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.

seekingalpha.com - 2026-07-11 07:09:31

July's GVAS Dogs list highlights ten fair-priced, high-yield large-cap stocks, including IRSA Inversiones, Weibo, Verizon, and AT&T, as ideal buys. Analyst targets project average net gains of 40.39% for the top ten GVAS stocks by July 2027, with risk profiles generally below market volatility. The dividend dogcatcher strategy favors stocks whose $1K dividend income exceeds share price, with 36 of 54 GVAS stocks meeting this ideal condition.

seekingalpha.com - 2026-07-11 06:01:57

Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.

seekingalpha.com - 2026-07-11 05:45:18

Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress suggests it can compete with GLP-1 drugs from Eli Lilly and Novo Nordisk.

fool.com - 2026-07-10 19:15:00

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-10 13:10:26

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patient.

businesswire.com - 2026-07-10 11:23:00

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-07-10 09:56:23

McDonald's (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now?

247wallst.com - 2026-07-10 08:40:47

Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.

247wallst.com - 2026-07-09 12:25:59

Income investors watching the calendar have a narrow window this week. Three of the market's most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears.

247wallst.com - 2026-07-08 16:07:27

The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist.

247wallst.com - 2026-07-08 10:26:38

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-08 10:01:09

They may not remain cheap for too much longer.

fool.com - 2026-07-07 18:30:00

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

247wallst.com - 2026-07-07 13:19:51

Pfizer's estimated 2026 earnings easily cover its generous dividend. But Pfizer faces a patent cliff, and cash flow didn't cover the dividend last year.

fool.com - 2026-07-07 11:45:00

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

zacks.com - 2026-07-07 10:06:11

Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.

247wallst.com - 2026-07-07 08:30:27

Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.

zacks.com - 2026-07-06 18:46:11

HSBC downgraded Pfizer Inc. (NYSE:PFE) on Monday, citing that the company's near-term re-rating prospects have weakened despite its attractive dividend yield and long-term oncology ambitions.

benzinga.com - 2026-07-06 14:14:30

Rick Ducat points to Pfizer (PFE) as an underperformer in the healthcare sector and greater S&P 500 (SPX). However, shares of the company show some signs of strength that Rick believes sets the stage for a rebound even after the stock was hit with a recent downgrade.

youtube.com - 2026-07-06 10:00:13

One stands above the others.

fool.com - 2026-07-06 08:37:00

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

247wallst.com - 2026-07-06 07:52:28

Eight S&P 500 'safer' dividend dogs, including VICI, VZ, T, F, BEN, KMI, KEY, and RF, offer attractive yields with free cash flow coverage. Analyst projections for the top ten S&P 500 dividend dogs indicate potential net gains of 21.99% to 50.26% by July 2027, with an average risk 54% below market. The dividend dog strategy favors stocks where annual dividends from $1K invested exceed single share prices, signaling fair value and income potential.

seekingalpha.com - 2026-07-04 01:38:59

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

Pfizer has the funds to acquire more companies. Buying Kailera Therapeutics would help Pfizer establish a stronger foothold in the weight-loss market.

fool.com - 2026-07-02 17:00:00

Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat warm. Dividend income depends on a company writing a check every 90 days, and for a handful of blue chips, that check has... $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income

247wallst.com - 2026-07-02 11:02:53

Pfizer and Verizon Communications are extremely high-yielding dividend stocks that trade at low valuations. They have been raising their payouts for many years.

fool.com - 2026-07-01 10:00:00

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

zacks.com - 2026-07-01 09:16:09

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.

zacks.com - 2026-06-30 18:46:05

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows,... 3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market

247wallst.com - 2026-06-30 12:47:37

I keep buying Pfizer (NYSE:PFE | PFE Price Prediction) every time my brokerage cash builds up, and I am not slowing down.

247wallst.com - 2026-06-30 12:15:45

Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE | PFE Price Prediction).

247wallst.com - 2026-06-30 09:50:41

It could prove to be a case of better later than never for the healthcare giant.

fool.com - 2026-06-30 09:00:00

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

proactiveinvestors.com - 2026-06-30 08:19:00

This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.

marketwatch.com - 2026-06-29 16:43:00

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

fool.com - 2026-06-29 11:43:02

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb:... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target

247wallst.com - 2026-06-29 10:51:03

Why settle for puny yields when you can buy these monster dividend stocks?

fool.com - 2026-06-29 05:55:00